In subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage experienced cirrhosis reversal.

Fortress Biotech and its subsidiary Helocyte have announced the dosing of the first subject in a multi-centre Phase II trial ...

The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

HealthDay News — In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and Critical Care Medicine, updated ...

The WVU Cancer Institute is the first provider in the state to offer a new and promising treatment for extensive-stage small cell lung cancer. Extensive stage means the cancer has spread within the ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Adagene (ADAG) announced updated clinical data from ADG126 in microsatellite stable colorectal cancer, MSS CRC, at the ASCO Gastrointestinal ...

Press Release ImmunoMet Therapeutics, Inc., ("ImmunoMet", or the "Company"), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today provided a data ...

A revolutionary new treatment for breast cancer has shown the ability to eliminate small breast tumors and significantly ...

During the COVID-19 pandemic, when fentanyl overdoses surged, doctors were desperate to find ways of helping their patients.